• Record receipts from customers of $5M, up 57% from previous quarter
• Positive cashflows from operating activities of $1.1M
• Major clinical trial contract wins totalling $20.1M since Aug 2023

Resonance Health Ltd (ASX: RHT) has released its Appendix 4C and Quarterly Activities & Cashflow Report for the quarter ended 31 December 2024. The company continued to rapidly and profitably scale up its operations, achieving record receipts from customers of $5M for the quarter, an increase of 57% compared to the previous quarter and an increase of 134% over the December 2023 receipts. The company's 12-month rolling receipts reached $13.1M, more than the total receipts received during the three financial years from FY2021 to FY2023 combined. The company reported positive cashflows from operating activities of $1.1M and net positive cashflows from operating activities of $2.5M for the 12 months to 31 December 2024. The company's CRO Services business unit won another trial worth $13.8M over 24 months, taking total contract wins to over $20M since August 2023. The TrialsWest business continued to trade strongly, and the company paid deferred consideration of $3.2M to the TrialsWest vendors during the quarter. The company also agreed to provide a new central-read analysis service for Magnetic Resonance Elastography (MRE) to the major clinical trial announced in November 2024. The company's balance sheet remains strong, with a cash balance of $3.5M at the end of the quarter and net cash of $0.5M (net of $3.0M bank debt).

The company reported record receipts from customers of $5M for the quarter, up 57% from the previous quarter and up 134% from the same period in the prior year. The company's 12-month rolling receipts reached $13.1M, a significant step-change in the company's cashflow profile.

The company continues to rapidly and profitably scale up its operations, with the execution of its strategy to drive growth in its 3-business focus areas - Software-as-a-Medical Device (SaMD), Clinical Trial Management (CRO Services), and Clinical Trial Site Services (TrialsWest). The company has a strong pipeline of new business opportunities and is well-positioned to capitalize on the growing demand for its services.